Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.43 |
| ▸ | CETP | P11597 | 4/20 | 0.41 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5135486 | 0.95 | C5AR1 (0.42) | C5AR1CETPTRPC5CRHR1NR3C1 | |
| SCHEMBL5135861 | 0.95 | CRHR1 (0.44) | C5AR1CETPTRPC5CRHR1TSHR | |
| SCHEMBL650074 | 0.92 | C5AR1 (0.43) | C5AR1CETPCRHR1 | |
| SCHEMBL5138032 | 0.92 | C5AR1 (0.43) | C5AR1CRHR1TSHRPTGDR2 | |
| SCHEMBL648971 | 0.91 | C5AR1 (0.42) | C5AR1CRHR1 | |
| SCHEMBL648222 | 0.89 | C5AR1 (0.43) | C5AR1CRHR1TSHRBCHEHSD17B10 | |
| SCHEMBL5135433 | 0.89 | C5AR1 (0.46) | C5AR1TSHRBCHEHSD17B10 | |
| SCHEMBL5135374 | 0.89 | C5AR1 (0.40) | C5AR1CETPTRPC5CRHR1 | |
| SCHEMBL649258 | 0.88 | C5AR1 (0.45) | C5AR1TSHRBCHEHSD17B10 | |
| SCHEMBL651407 | 0.88 | C5AR1 (0.42) | C5AR1CETPCRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |